Document ID: chunk:federal_register_of_legislation:F2020L01391:reg:9:p1
Version: federal_register_of_legislation:F2020L01391
Segment Type: reg
Provision Reference: reg 9 (pt 1/3)
Character Range: 3410–6634

9               Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting spinal adhesive arachnoiditis or death from spinal adhesive arachnoiditis with the circumstances of a person's relevant service:
(1)          having severe spinal trauma involving the affected site within the ten years before the clinical onset of spinal adhesive arachnoiditis;
Note: severe spinal trauma is defined in the Schedule 1 - Dictionary.
(2)          undergoing spinal surgery involving the affected site within the ten years before the clinical onset of spinal adhesive arachnoiditis;
Note: Examples of spinal surgery include spinal fusion, laminectomy and discectomy.
(3)          having a lumboperitoneal shunt at the affected site at the time of the clinical onset of spinal adhesive arachnoiditis;
(4)          having an epidural blood patch within the three months before the clinical onset of spinal adhesive arachnoiditis;
(5)          having a myelogram involving an injection of oil-soluble intrathecal radiological contrast agent before the clinical onset of spinal adhesive arachnoiditis;
(6)          having a myelogram involving an injection of water-soluble intrathecal radiological contrast agent from the specified list of radiological contrast agents within the ten years before the clinical onset of spinal adhesive arachnoiditis;
Note: specified list of radiological contrast agents is defined in the Schedule 1 - Dictionary.
(7)          having an injection of Thorotrast (thorium dioxide suspension) into the subarachnoid space before the clinical onset of spinal adhesive arachnoiditis;
(8)          having intrathecal injection of methylprednisolone acetate (Depo-Medrol) within the two years before the clinical onset of spinal adhesive arachnoiditis;
(9)          having an in situ intrathecal drug delivery system at the affected site at the time of the clinical onset of spinal adhesive arachnoiditis;
(10)      having intrathecal injection of methotrexate or cytosine arabinoside within the one year before the clinical onset of spinal adhesive arachnoiditis;
(11)      having intrathecal injection of radioactive gold at the affected site before the clinical onset of spinal adhesive arachnoiditis;
(12)      having an infection from the specified list of infections before the clinical onset of spinal adhesive arachnoiditis;
Note: specified list of infections is defined in the Schedule 1 - Dictionary.
(13)      having a subarachnoid haemorrhage within the ten years before the clinical onset of spinal adhesive arachnoiditis;
(14)      having a spinal subdural haematoma at the affected site within the two years before the clinical onset of spinal adhesive arachnoiditis;
(15)      having ankylosing spondylitis involving the affected site before the clinical onset of spinal adhesive arachnoiditis;
(16)      having an intervertebral disc prolapse causing spinal stenosis at the affected site at the time of the clinical onset of spinal adhesive arachnoiditis;
(17)      having sarcoidosis before the clinical onset of spinal adhesive arachnoiditis;
(18)      having severe spinal trauma involving